Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (Nature Communications, (2022), 13, 1, (5258), 10.1038/s41467-022-32828-6)

Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina ViaplanaJavier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra

    Résultats de recherche: Contribution à un journal!!Comment/debate

    Résumé

    The original version of the Supplementary Information associated with this Article included an incorrect Supplementary Information file, inwhich tracked changes fromrevision werepresent. The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version can be found as Supplementary Information associated with this Correction. In the original version of the published article, the Acknowledgements section omitted a grant number. The correct Acknowledgements paragraph includes the following: This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540). This has now been corrected both in the HTML and the PDF versions of the article.

    langue originaleAnglais
    Numéro d'article6928
    journalNature Communications
    Volume13
    Numéro de publication1
    Les DOIs
    étatPublié - 1 déc. 2022

    Contient cette citation